Genentech, Inc.
NEWS
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
The FDA granted the designation based on data from a mid-stage trial that examined the safety and efficacy of Esbriet in this indication.
In its announcement, Bicycle did not identify the cancer targets it will focus on in its collaboration with Genentech.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
It was a very busy week for clinical trial news. Here’s a look.
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.
JOBS
IN THE PRESS